glp-1 agonists with cardiovascular benefit The Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-Level Outcomes to Micro-Level Mechanisms Bridging the gap between GLP1-receptor

Also, other pathogens have been linked to DPP4

Managing GI Side Effects# Regardless of the specific drug, several strategies can mitigate GI adverse events: Slow titration: Following or extending the recommended dose escalation schedule Dietary modification: Smaller meals, avoiding high-fat foods, eating slowly Timing: Taking the injection (or pill) at a consistent time, often in the evening Hydration: Maintaining adequate fluid intake to offset effects of reduced food intake Anti-emetics: Short-term use during dose escalation if needed What to Watch# Ecnoglutide and CT-388 Phase 3 data -- Will the tolerability advantage of biased agonism hold in larger, longer trials

Glucagon-like peptide-1 secretion in people with versus without type 2 diabetes: a systematic review and meta-analysis of cross-sectional studies

Regional procurement mechanisms, such as pooled purchasing initiatives through the WHO or regional health organizations, could substantially lower costs

Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake

Originally used to treat type 2 diabetes, GLP1 medications are now also widely used for weight management